Table 2. Initial clinical presentation, initial laboratory results, and clinical outcomes of patients who presented with GI bleed in both groups.
| Dabigatran | Warfarin | P value | |
|---|---|---|---|
| Initial presentation | |||
| UGIB n, (%) | 0 | 1 (3.8) | – |
| LGIB n, (%) | 11 (84.6) | 20 (76.9) | 0.61 |
| Symptomatic anemia n, (%) | 2 (15.4) | 5 (19.2) | 0.81 |
| Hypotension n, (%) | 1(7.7) | 8(30.8) | 0.11 |
| Tachycardia n, (%) | 3 (23.0) | 5 (19.0) | 0.78 |
| Initial Hb at presentation (mg/dL) | 10.4±2.1 | 9.6±2.6 | 0.34 |
| Second Hb within 24 hr (mg/dL) | 9.64±1.3 | 9.01±2.4 | 0.31 |
| Platelet count (103/mm3) | 189±60 | 240±89 | 0.045 |
| Creatinine (mg/dL) | 1.35±1 | 1.35±0.8 | 0.99 |
| INR | 1.81±0.9 | 2.54±0.3 | 0.01 |
| AKI n, (%) | 4 (31.0) | 5 (19.0) | 0.42 |
| PRBC transfusion (units) | 0.69±1.1 | 1.92±2.2 | 0.024* |
| Length of stay (days) | 5.6±4.9 | 5.9±4 | 0.86 |
| ICU n, (%) | 1 (7.7) | 1 (3.8) | 0.61 |
| Death n, (%) | 1 (7.7) | 1 (3.8) | 0.61 |
| Endoscopy n, (%) | 6 (46.0) | 15 (58.0) | 0.50 |
*, after multiple regression analysis correcting for history of CKD, and hemoglobin level at presentation, there is significant association between initial hemoglobin level at presentation, type of anticoagulation, and the quantity of PRBC transfusion with the higher amount of transfused PRBCs in the warfarin group. GI, gastrointestinal; UGIB, upper gastrointestinal bleeding; LGIB, lower gastrointestinal bleeding; Hb, hemoglobin; INR, international normalized ratio; AKI, acute kidney injury; PRBC, packed red blood cell; ICU, intensive care unit; CKD, chronic kidney disease.